Sage Journals: Discover world-class research

Abstract

BACKGROUND:

Pneumococcal infections are a leading global cause of morbidity and mortality, complicated by the increasing antimicrobial resistance of pneumococcal isolates.

OBJECTIVE:

To evaluate morbidity and mortality associated with both invasive pneumococcal disease (IPD) and non-IPD in Jamaica in both the paediatric and adult population. Pneumococcal isolates ( $n=$ 94) were collected over a 2-year period (2008–2009).

METHODS:

Risk factors for poor clinical outcomes: death, complicated disease and length of hospitalization (LOH) were evaluated and antimicrobial resistance patterns were determined by Kirby-Bauer disc diffusion.

RESULTS:

The case fatality rate was 6.8%. Independent mortality risk factors included complicated disease [OR 30.9 (3.4–276.6)] and diabetes mellitus [OR 8.3 (1.4–48.8)]. Independent risk factors for the development of complicated disease included sickle cell disease [OR 36.5 (4.2–320.3)] and sepsis [OR 3.5 (1.2–10.4)]. The LOH was increased most in patients with invasive disease (4.6-fold) and resistance to ceftriaxone (4.3-fold). Penicillin (16.0%) and erythromycin (14.9%) resistance was most prevalent, while ceftriaxone (4.3%) resistance was least prevalent.

CONCLUSIONS:

The high burden of IPD in at-risk groups in our population and the associated increase in morbidity and mortality underlie the need for improved preventive and therapeutic management strategies in these patients.

Keywords

Pneumococcus streptococcus pneumoniae morbidity mortality jamaica

Get full access to this article

View all access options for this article.

References

Allen

U.D.

Thomas

Carapetis

Henry

Wasfy

Lovgren

Richardson

and Low

D.E.

, Serotypes of respiratory tract isolates of Streptococcus pneumoniae from Jamaican children, Int J Infect Dis 7 (2003), 29–35.

Charalambous

B.M.

Batt

S.L.

Peek

A.C.

Mwerinde

Sam

and Gillespie

S.H.

, Quantitative validation of media for transportation and storage of Streptococcus pneumoniae, J Clin Microbiol 41 (2003), 5551–5556.

Cherazard

Epstein

Doan

T.L.

Salim

Bharti

and Smith

M.A.

, Antimicrobial Resistant Streptococcus pneumoniae: Prevalence, Mechanisms, and Clinical Implications, Am J Ther 24 (2017), e361–e369.

Corcoran

Vickers

Mereckiene

Murchan

Cotter

Fitzgerald

McElligott

Cafferkey

O’Flanagan

Cunney

and Humphreys

, The epidemiology of invasive pneumococcal disease in older adults in the post-PCV era, Has there been a herd effect? Epidemiol Infect 145 (2017), 2390–2399.

Feldman

and Anderson

, Recent advances in our understanding of Streptococcus pneumoniae infection, F1000Prime Rep 6 (2014), 82.

Hardie

King

Fraser

and Reid

, Prevalence of pneumococcal polysaccharide vaccine administration and incidence of invasive pneumococcal disease in children in Jamaica aged over 4 years with sickle cell disease diagnosed by newborn screening, Ann Trop Paediatr 29 (2009), 197–202.

Iannella

H.A.

and Luna

C.M.

, Community-Acquired Pneumonia in Latin America, Semin Respir Crit Care Med 37 (2016), 868–875.

Johnson

A.P.

Waight

Andrews

Pebody

George

R.C.

and Miller

, Morbidity and mortality of pneumococcal meningitis and serotypes of causative strains prior to introduction of the 7-valent conjugant pneumococcal vaccine in England, J Infect 55 (2007), 394–399.

Klemets

Lyytikainen

Ruutu

Ollgren

and Nuorti

J.P.

, Invasive pneumococcal infections among persons with and without underlying medical conditions: Implications for prevention strategies, BMC Infect Dis 8 (2008), 96.

10.

Lynch

J.P.

, 3rd and Zhanel

G.G.

, Streptococcus pneumoniae: Epidemiology, risk factors, and strategies for prevention, Semin Respir Crit Care Med 30 (2009), 189–209.

11.

McGregor

Barton

Thomas

and Christie

C.D.

, Invasive pneumococcal disease in Jamaican children, Ann Trop Paediatr 24 (2004), 33–40.

12.

Mitchell

A.M.

and Mitchell

T.J.

, Streptococcus pneumoniae: Virulence factors and variation, Clin Microbiol Infect 16 (2010), 411–418.

13.

MOH, HIV Epidemic Update - Facts and Figures, in, National HIV/STI Program, Jamaica HIV/AIDS Epidemic Update, 2011.

14.

Munroe

, Pneumococcal and vaccine use: Jamaican experience, 2008.

15.

Ortqvist

Hedlund

and Kalin

, Streptococcus pneumoniae: Epidemiology, risk factors, and clinical features, Semin Respir Crit Care Med 26 (2005), 563–574.

16.

Reinert

R.R.

, The antimicrobial resistance profile of Streptococcus pneumoniae, Clin Microbiol Infect 15(Suppl 3) (2009), 7–11.

17.

SAGE, Pneumococcal vaccines: WHO position paper, Weekly Epidemiological Record 14 (2012), 129–144.

18.

Spellerberg

and Brandt

, Streptococcus, in: Manual of Clinical Microbiology Jorgensen

J.H.

Pfaller

Carroll

K.C.

Funke

Landry

M.L.

Richter

and Warnock

D.W.

, ed., ASM Press, Washington, 2015, pp. 383–402.

19.

Wong

W.Y.

Overturf

G.D.

and Powars

D.R.

, Infection caused by Streptococcus pneumoniae in children with sickle cell disease: Epidemiology, immunologic mechanisms, prophylaxis, and vaccination, Clin Infect Dis 14 (1992), 1124–1136.

Morbidity,mortality and antimicrobial resistance of pneumococcal infections in the Jamaican paediatric and adult populations